Colon Cancer, Version 3.2014

被引：203

作者：

Benson, Al B., III ^{[1
]}

Venook, Alan P. ^{[2
]}

Bekaii-Saab, Tanios ^{[3
,4
]}

Chan, Emily ^{[5
]}

Chen, Yi-Jen ^{[6
]}

Cooper, Harry S. ^{[7
]}

Engstrom, Paul F. ^{[7
]}

Enzinger, Peter C. ^{[8
]}

Fenton, Moon J. ^{[9
]}

Fuchs, Charles S. ^{[8
]}

Grem, Jean L. ^{[10
]}

Hunt, Steven ^{[11
,12
]}

Kamel, Ahmed ^{[13
]}

Leong, Lucille A. ^{[6
]}

Lin, Edward ^{[14
]}

Messersmith, Wells ^{[15
]}

Mulcahy, Mary F. ^{[1
]}

Murphy, James D. ^{[16
]}

Nurkin, Steven ^{[17
]}

Rohren, Eric ^{[18
]}

Ryan, David P. ^{[19
]}

Saltz, Leonard ^{[20
]}

Sharma, Sunil ^{[21
]}

Shibata, David ^{[22
]}

Skibber, John M. ^{[18
]}

Sofocleous, Constantinos T. ^{[20
]}

Stoffel, Elena M. ^{[23
]}

Stotsky-Himelfarb, Eden ^{[24
]}

Willett, Christopher G. ^{[25
]}

Gregory, Kristina M.

Freedman-Cass, Deborah A.

机构：

[1] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA

[2] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA

[3] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA

[4] Solove Res Inst, Columbus, OH USA

[5] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[6] City Hope Comprehens Canc Ctr, Duarte, CA USA

[7] Fox Chase Canc Ctr, Philadelphia, PA USA

[8] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA

[9] Univ Tennessee, Hlth Sci Ctr, St Jude Childrens Res Hosp, Knoxville, TN 37996 USA

[10] Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE USA

[11] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA

[12] Washington Univ, Sch Med, St Louis, MO 63130 USA

[13] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL USA

[14] Seattle Canc Care Alliance, Fred Hutchinson Canc Res Ctr, Seattle, WA USA

[15] Univ Colorado, Ctr Canc, Boulder, CO 80309 USA

[16] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA

[17] Roswell Pk Canc Inst, Buffalo, NY USA

[18] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[19] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA

[20] Mem Sloan Kettering Canc Ctr, New York, NY USA

[21] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA

[22] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[23] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA

[24] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA

[25] Duke Canc Inst, Durham, NC USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2014年 / 12卷 / 07期

关键词：

METASTATIC COLORECTAL-CANCER; GROWTH-FACTOR RECEPTOR; CAPECITABINE PLUS OXALIPLATIN; PHASE-III TRIAL; KRAS WILD-TYPE; HIGH-DOSE LEUCOVORIN; 1ST-LINE COMBINATION CHEMOTHERAPY; UNRESECTABLE LIVER METASTASES; POSTPROGRESSION SURVIVAL-TIME; BEVACIZUMAB-CONTAINING ARMS;

D O I：

10.6004/jnccn.2014.0099

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

The NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance, management of recurrent and metastatic disease,and survivorship. This portion of the guidelines focuses on the use of systemic therapy in metastatic disease. The management of metastatic colorectal cancer involves a continuum of care in which patients are exposed sequentially to a variety of active agents, either in combinations or as single agents. Choice of therapy is based on the goals of treatment, the type and timing of prior therapy, the different efficacy and toxicity profiles of the drugs, the mutational status of the tumor, and patient preference.

引用

页码：1028 / 1059

页数：32

共 242 条

[1]

Commentary: Radiofrequency ablation for colorectal liver metastases: do not blame the biology when it is the technology [J].

Abdalla, Eddie K. .

AMERICAN JOURNAL OF SURGERY, 2009, 197 (06) :737-739

[2]

Adam R, 2004, ANN SURG, V240, P644, DOI 10.1097/01.sla.0000141198.92114.16

[3]

Adam R, 2001, ANN SURG ONCOL, V8, P347

[4]

Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group Phase II study [J].

Alberts, SR ;

Horvath, WL ;

Stcrnfeld, WC ;

Goldberg, RM ;

Mahoney, MR ;

Dakhil, SR ;

Levitt, R ;

Rowland, K ;

Nair, S ;

Sargent, DJ ;

Donohue, JH .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (36) :9243-9249

[5]

Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08 [J].

Allegra, Carmen J. ;

Yothers, Greg ;

O'Connell, Michael J. ;

Sharif, Saima ;

Petrelli, Nicholas J. ;

Colangelo, Linda H. ;

Atkins, James N. ;

Seay, Thomas E. ;

Fehrenbacher, Louis ;

Goldberg, Richard M. ;

O'Reilly, Seamus ;

Chu, Luis ;

Azar, Catherine A. ;

Lopa, Samia ;

Wolmark, Norman .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (01) :11-16

[6]

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].

Amado, Rafael G. ;

Wolf, Michael ;

Peeters, Marc ;

Van Cutsem, Eric ;

Siena, Salvatore ;

Freeman, Daniel J. ;

Juan, Todd ;

Sikorski, Robert ;

Suggs, Sid ;

Radinsky, Robert ;

Patterson, Scott D. ;

Chang, David D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634

[7]

CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer [J].

André, T ;

Louvet, C ;

Maindrault-Goebel, F ;

Couteau, C ;

Mabro, M ;

Lotz, JP ;

Gilles-Amar, V ;

Krulik, M ;

Carola, E ;

Izrael, V ;

de Gramont, A .

EUROPEAN JOURNAL OF CANCER, 1999, 35 (09) :1343-1347

[8]

[Anonymous], SAF AV BEV

[9]

[Anonymous], 2012, STIVARGA PACK INS

[10]

[Anonymous], J CLIN ONCOL S

← 1 2 3 4 5 6 7 8 9 10 →